Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/JBM.S39220 http://scihub22266oqcxt.onion/10.2147/JBM.S39220 C4039396!4039396 !24899824     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24899824 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Blood+Med 2014 ; 5 (ä): 59-68 Nephropedia Template TP {{tp|p=24899824 |t=2014. Targeting GPVI as a novel antithrombotic strategy |pdf=|usr=}}{{24899824 }} gab.com Text Targeting GPVI as a novel antithrombotic strategy JO: J Blood Med http://www.kidney.de/pget.php?&tw=1&pmid=24899824 #FOAvip While platelet activation is essential to maintain blood vessel patency and minimize loss of blood upon injury, untimely or excessive activity can lead to unwanted platelet activation and aggregation. Resultant thrombosis has the potential to block blood vessels, causing myocardial infarction or stroke. To tackle this major cause of mortality, clinical therapies that target platelet responsiveness (antiplatelet therapy) can successfully reduce cardiovascular events, especially in people at higher risk; however, all current antiplatelet therapies carry an increased probability of bleeding. This review will evaluate new and emerging targets for antithrombotics, focusing particularly on platelet glycoprotein VI, as blockade or depletion of this platelet-specific receptor conveys benefits in experimental models of thrombosis and thromboinflammation without causing major bleeding complications. Twit Text FOAVip Targeting GPVI as a novel antithrombotic strategy ????J Blood Med http://www.kidney.de/pget.php?&tw=1&pmid=24899824 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24899824 #FOAvip English Wikipedia <ref>{{Cite pmid|24899824 }}</ref> Targeting GPVI as a novel antithrombotic strategy #MMPMID24899824 Andrews RK ; Arthur JF ; Gardiner EE J Blood Med 2014[]; 5 (ä): 59-68 PMID24899824 show ga While platelet activation is essential to maintain blood vessel patency and minimize loss of blood upon injury, untimely or excessive activity can lead to unwanted platelet activation and aggregation. Resultant thrombosis has the potential to block blood vessels, causing myocardial infarction or stroke. To tackle this major cause of mortality, clinical therapies that target platelet responsiveness (antiplatelet therapy) can successfully reduce cardiovascular events, especially in people at higher risk; however, all current antiplatelet therapies carry an increased probability of bleeding. This review will evaluate new and emerging targets for antithrombotics, focusing particularly on platelet glycoprotein VI, as blockade or depletion of this platelet-specific receptor conveys benefits in experimental models of thrombosis and thromboinflammation without causing major bleeding complications. äTargeting GPVI as a novel antithrombotic strategy (epmc).pdf DeepDyve Pubget Overpricing